Beam Therapeutics Inc. BEAM
Regular-session close
After hours · Nov 20, 6:53 PM ET
- YTD
- -24.60%
- 1 year
- +1.46%
5D -1.74 (-7.69%)
- Market cap
- 2.16B
- Revenue (ttm)
- 146.64M
- Profit margin
- -73.89%
- EPS (ttm)
- -0.87
- Shares out
- 103.50M
- Forward P/E
- -4.05
- YTD return
- -24.60%
- 1-year return
- +1.46%
- 50-day average
- 24.70
- 200-day average
- 27.74
- Volume
- 3.89M
- Avg volume
- 2.02M
- Open
- 20.54
- Previous close
- 20.94
- Day's range
- 20.54 – 22.10
- 52-week range
- 20.60 – 37.92
- Beta
- 2.22
- Analysts
- Strong Buy
- Price target
- 49.85 (+138.5%)
- Earnings date
- Feb 23, 2027
Key statistics
- Enterprise value
- 1.29B
- Price / sales
- 14.75
- Price / book
- 2.19
- Revenue growth
- -96.80%
- Free cash flow
- -262.63M
- Total cash
- 1.04B
- Total debt
- 243.87M
- Return on equity
- -11.29%
- Short % of float
- 38.92%
Fundamental scorecard
9 of 25 checks passed on BEAM’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 26.00
- Target (mean)
- 49.85
- Target (high)
- 80.00
- Strong buy1
- Buy12
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate -1.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | -1.28 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -1.15 | -1.28 | -0.13 | -11.30% |
| Aug 4, 2026 | Jun 30, 2026 | -1.11 | -1.18 | -0.07 | -6.31% |
| May 7, 2026 | Mar 31, 2026 | -0.87 | -0.91 | -0.04 | -4.60% |
| Feb 24, 2026 | Dec 31, 2025 | -1.13 | -0.10 | +1.03 | +91.15% |
| Nov 4, 2025 | Sep 30, 2025 | -0.98 | -1.10 | -0.12 | -12.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Wedbush | main | Outperform | Outperform |
| Nov 5, 2026 | Guggenheim | main | Buy | Buy |
| Nov 4, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 4, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 28, 2026 | Wedbush | main | Outperform | Outperform |
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- beamtx.com
News
Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $33
Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30
Beam Therapeutics To Present Updated Data From Its BEACON Phase 1/2 Study Of Ristoglogene Autogetemcel In Sickle Cell Disease At 68th American Society of Hematology Annual Meeting
Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate
Bears Load Up on Ondas, Dutch Bros and 8 More Stocks — Is a Squeeze Brewing? Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79
Your note
Sign in to keep a note on BEAM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELLON CHRISTINE | Officer | Sale | Mar 31, 2026 | 109,711 |
| CAVANAGH BETHANY J | Officer and Treasurer | Sale | Mar 31, 2026 | 51,171 |
| CIARAMELLA GIUSEPPE | President | Conversion of Exercise of derivative security | Jun 16, 2026 | 253,911 |
| EMANY SRAVAN KUMAR | Chief Financial Officer | Stock Award(Grant) | Mar 30, 2026 | 105,456 |
| EVANS JOHN M. | Chief Executive Officer | Sale | Jun 29, 2026 | 1,150,200 |
| FMR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 25, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.49% | 12,926,476 | 270.16M | Sep 29, 2026 |
| ARK Investment Management, LLC | 11.41% | 11,805,372 | 246.73M | Sep 29, 2026 |
| Farallon Capital Management LLC | 9.93% | 10,276,396 | 214.78M | Sep 29, 2026 |
| Blackrock Inc. | 8.81% | 9,119,097 | 190.59M | Sep 29, 2026 |
| State Street Corporation | 5.72% | 5,920,492 | 123.74M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.74% | 4,901,651 | 102.44M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 6.00% | 6,207,008 | 129.73M | Oct 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.34% | 3,457,347 | 72.26M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.33% | 3,441,420 | 71.93M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 3,273,307 | 68.41M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.98% | 3,086,450 | 64.51M | Oct 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 2,569,276 | 53.70M | Sep 29, 2026 |
